

TECHNICAL DATA SHEET

# Recombinant Mouse VEGF-165 (Carrier-free)

Catalog Number: 21-8351

**RPx-Pro™ Recombinant Protein**  
PRODUCT INFORMATION

**CONTENTS**

Recombinant Mouse VEGF-165 (Carrier-free)

**DESCRIPTION**

VEGFs are a family of molecules that are key drivers of vascularization and angiogenic processes. VEGFs induce proliferation and homeostasis of endothelial cells. VEGFs have been studied as indicators of both normal and pathogenic angiogenesis particularly involving tumor cells. Overexpression of VEGF in tumor cells allows tumor growth and enhanced metastatic potential. VEGF family members stimulate cellular responses by binding to VEGF receptors that include fms-like tyrosine kinase (flt-1), KDR gene product (the Mouse homolog of KDR is the flk-1 gene product), and the flt4 gene product. Splicing of the exon 6 or exon 7 mRNA from the 8 exon VEGF gene results in the different amino acid number and variants in humans and mice accounting for VEGF<sub>121</sub>, VEGF<sub>165</sub> and others (one amino acid less in mouse analogs). These variants differ in their binding to heparin sulfate proteoglycans and neuropilin co-receptors imparting differential binding and activation through VEGFRs and variant specific angiogenic or anti-angiogenic functions. VEGFs and VEGFRs are targets for therapeutic intervention.

**MOLECULAR MASS**

Recombinant Mouse VEGF<sub>165</sub> is a 39.0 kDa protein composed of two 165 amino acid residues.

**AMINO ACID SEQUENCE**

MAPTTEGEQK SHEVIKFM DV YQRSYCRPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCAGC CNDEALECVP TSESNITMQI MRIKPHQSQH IGEMSFLQHS RCECRPKKDR TKPEKHCEPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR

**SOURCE**

E. Coli

**APPLICATIONS**

Bioassay

**PURITY**

98 %

**STORAGE**

-20°C

**PROTEIN CONTENT**

Content Verified by UV Spectroscopy and/or SDS-PAGE

**ENDOTOXIN LEVEL**

Endotoxin level is <0.1 ng/μg of protein (<1 EU/μg).

**AUTHENTICITY**

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

**CROSS REACTIVITY**

Chicken, Human, Rabbit, Rat

**BIOACTIVITY**

Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-5.0 ng/ml.

**RESEARCH AREAS**

Angiogenesis/Cardiovascular; Cancer; Inflammation; Proliferation

**RECONSTITUTION**

See Certificate of Analysis (COA) for lot specific reconstitution information.

**REFERENCES**

Karkkainen M and TV Petrova 2000 Oncogene 19: 5598–5605. Shin YJ, JS Choi, et al. 2010 J Neuroimmunol 229: 81-90. Holmes K, OL Roberts, AM Thomas and MJ Cross 2007 Cell Signal 19: 2003–2012. Bergers G and D Hanahan 2008 Nat Rev Cancer 8: 592–603. Paez-Ribes M, E Allen, JHudock, T Takeda, H Okuyama, F Vinals, M Inoue, G Bergers, D Hanahan and O Casanovas Cancer Cell 15: 220–231. Ebos J, CR Lee, W Cruz-Munoz, GA Bjarnason, JG Christensen and RS Kerbel 2009 Cancer Cell 15: 232–239.

Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.

Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Tonbo Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Tonbo Biosciences, Tonbo Biosciences Logo and all other trademarks are the property of Tonbo Biotechnologies Corporation. © 2013 Tonbo Biosciences.